(Dow Pharmaceuticals, 10 Weeks)
Sadick Research Group is conducting a clinical study of pediatric and adult patients receiving a topical treatment for atopic dermatitis (eczema).
Gender: Male and Female
Minimum Age: 2 Years Old
Maximum Age: N/A
Facility Type: Outpatient
Stipend Range: Up to $525 Upon Study Completion
Study Length: 10 Weeks
Sponsor: Dow Pharmaceuticals
This is a multicenter double-blind, randomized, placebo-controlled study to assess the efficacy and safety of IDP-124 lotion for the treatment of moderate to severe atopic dermatitis (eczema). All enrolled subjects will receive a lotion medication to be applied twice daily for 6 weeks. There are 7 office visits throughout the study and can include a physical exam, blood draws, urine sampling, assessments by qualified professionals and other assessments which will be reviewed in detail at your screening visit. All services are provided at no cost.
Inclusion and Exclusion Criteria
Eligible male and female participants will be 2 years of age or older and have a diagnosis of moderate to severe atopic dermatitis. Female subjects cannot plan to be pregnant or breast feeding during the study. Subjects must be available for the 7 office visits during the study and be willing to comply with all study instructions. Several other restrictions and criteria may apply that the study doctor will review with you to determine if you qualify to enter the study.
Other Trial Details
- Physical exam and assessments of study condition to be provided at no cost by an experienced provider.
- No insurance necessary.
- Compensation will be provided at the end of study participation.